Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.
about
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?Children's Oncology Group's 2013 blueprint for research: bone tumorsComparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stressGene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology GroupMolecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group.BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization.RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma.Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis.Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent MechanismsIGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance.Functional Interactions in Transcription and Splicing of Ewing’s Sarcoma
P2860
Q26782649-D445BB21-05AC-463E-9F80-2B6CC1651C3FQ27027664-76AAACEF-EF14-42E4-884B-D56001FC4CC2Q34105623-1A133975-D594-46A9-B0D2-7A646AC2962BQ34652823-264B72EB-38C3-431F-9E45-D63E716C43F8Q35672183-4F02C3FD-B444-43ED-A676-7AE74F43CB93Q35688154-051244A7-C93E-4EEB-B8D8-9910190B808FQ35957998-EFFE7548-1BD2-4093-914E-D9B0FDCD972FQ36700671-0A3B5A8D-1E47-49F3-8729-184C275E24ECQ37408672-0B6FEE6A-07BF-49D5-9B96-4F54DBCC13CCQ37564718-89E5AFC4-B068-4B61-965F-D72471B7E312Q37740672-377FB102-7C22-4481-9898-3435D9B990C0Q37962606-73D50A5D-DAF5-4D94-B07B-25861873BB8BQ38951812-C572CCD8-8437-4F97-B4A8-8E3F9C7B0379Q41864004-A1FCD5EB-D078-43EB-A9A2-64483C1C3D44Q44518083-84E5F223-378C-43B4-98C5-E9E6C37ED453Q58991920-E3B389C0-8AC7-48AB-9AD5-10D4A12B8F53
P2860
Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Ewing tumors that do not overe ...... the Children's Oncology Group.
@en
Ewing tumors that do not overe ...... the Children's Oncology Group.
@nl
type
label
Ewing tumors that do not overe ...... the Children's Oncology Group.
@en
Ewing tumors that do not overe ...... the Children's Oncology Group.
@nl
prefLabel
Ewing tumors that do not overe ...... the Children's Oncology Group.
@en
Ewing tumors that do not overe ...... the Children's Oncology Group.
@nl
P2093
P2860
P1476
Ewing tumors that do not overe ...... the Children's Oncology Group.
@en
P2093
Dafydd Thomas
Darren Russell
Elizabeth R Lawlor
Hiroyuki Shimada
Jessie Hao-ru Hsu
John van Doorninck
Lingyun Ji
Mark Krailo
Richard B Womer
Richard Sposto
P2860
P356
10.1158/1078-0432.CCR-10-1417
P407
P577
2010-11-03T00:00:00Z